ProCE Banner Activity

Exploratory Analyses From a Phase I Study of Etavopivat in Sickle Cell Disease

Slideset Download
Conference Coverage
Etavopivat improved sickle RBC health and markers of sickle cell disease and pathophysiology in this phase I clinical study.

Released: December 17, 2021

Expiration: December 16, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation